Kinase inhibitors in multitargeted cancer therapy

Current Medicinal Chemistry

Volumn 24, Issue 16, 2017, Pages 1-16

  Gentile, Carla ^a   Martorana, Annamaria ^a   Lauria, Antonino ^a   Bonsignore, Riccardo ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Anticancer agents; Fda Approved drugs; Multitargeted drugs; Oncogene addiction; Polypharmacology; Tumor microenvironment; Tyrosine kinase receptors

Indexed keywords

ANTINEOPLASTIC AGENT; CABOZANTINIB; CRIZOTINIB; IMATINIB; PHOSPHOTRANSFERASE INHIBITOR; PONATINIB; PROTEIN TYROSINE KINASE; REGORAFENIB; SORAFENIB; SUNITINIB; TYROSINE KINASE RECEPTOR; VANDETANIB; ANILIDE; CARBANILAMIDE DERIVATIVE; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; N-(4-BROMO-2-FLUOROPHENYL)-6-METHOXY-7-((1-METHYLPIPERIDIN-4-YL)METHOXY)QUINAZOLIN-4-AMINE; NICOTINAMIDE; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDAZINE DERIVATIVE; PYRIDINE DERIVATIVE; PYRROLE DERIVATIVE; QUINAZOLINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVITY; FOOD AND DRUG ADMINISTRATION; HUMAN; MOLECULARLY TARGETED THERAPY; MULTITARGETED CANCER THERAPY; POLYPHARMACOLOGY; REVIEW; TUMOR MICROENVIRONMENT; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CHEMISTRY; METABOLISM; NEOPLASMS; PATHOLOGY;

ANILIDES; HUMANS; IMATINIB MESYLATE; IMIDAZOLES; INDOLES; NEOPLASMS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDAZINES; PYRIDINES; PYRROLES; QUINAZOLINES; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 85024398998     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867324666170112112734     Document Type: Review

References (124)

1. Van den Mooter, T.; Teuwen, L.-A.; Rutten, A.; Dirix, L. Trastuzumab Emtansine in Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. Expert Opin. Biol. Ther., 2015, 15, 749-760.
2. Yeung, Y.; Tebbutt, N.C. Bevacizumab in Colorectal Cancer: Current and Future Directions. Expert Rev. Anticancer Ther., 2012, 12, 1263-1273.
3. Li, S.; Qi, X.; Huang, Y.; Liu, D.; Zhou, F.; Zhou, C. Ceritinib (LDK378): A Potent Alternative to Crizotinib for ALK-Rearranged Non-Small-Cell Lung Cancer. Clin. Lung Cancer, 2015, 16, 86-91.
4. Cetin, B.; Gumusay, O.; Cengiz, M.; Ozet, A. Advances of Molecular Targeted Therapy in Gastric Cancer. J. Gastrointest. Cancer, 2016, 47, 125-134.
5. Rimawi, M.F.; Schiff, R.; Osborne, C.K. Targeting HER2 for the Treatment of Breast Cancer. Annu. Rev. Med., 2015, 66, 111-128.
6. Mateo, J.; Smith, A.; Ong, M.; de Bono, J.S. Novel Drugs Targeting the Androgen Receptor Pathway in Prostate Cancer. Cancer Metastasis Rev., 2014, 33, 567-579.
7. Koukourakis, G.V.; Sotiropoulou-Lontou, A. Targeted Therapy with Bevacizumab (Avastin) for Metastatic Colorectal Cancer. Clin. Transl. Oncol. Off. Publ. Fed. Span. Oncol. Soc. Natl. Cancer Inst. Mex., 2011, 13, 710-714.
8. Lauria, A.; Bonsignore, R.; Bartolotta, R.; Perricone, U.; Martorana, A.; Gentile, C. Drugs Polypharmacology by in Silico Methods: New Opportunities in Drug Discovery. Curr. Pharm. Des., 2016, 22, 3073-3081.
9. Weinstein, B. Relevance of the Concept of Oncogene Addiction to Hormonal Carcinogenesis and Molecular Target ing in Cancer Prevention and Therapy. Adv. Exp. Med. Biol., 2008, 617, 3-13.
10. Faber, A.C.; Wong, K.-K.; Engelman, J.A. Differences Underlying EGFR and HER2 Oncogene Addiction. Cell Cycle Georget. Tex, 2010, 9, 851-852.
11. Huang, H.; Weng, H.; Zhou, H.; Qu, L. Attacking c-Myc: Targeted and Combined Therapies for Cancer. Curr. Pharm. Des., 2014, 20, 6543-6554.
12. Li, Y.; Choi, P.S.; Felsher, D.W. Oncogene Addiction: Resetting the Safety Switch? Oncotarget, 2014, 5, 7986-7987.
13. Huang, L.; Xu, A.-M.; Liu, S.; Liu, W.; Li, T.-J. Cancer-Associated Fibroblasts in Digestive Tumors. World J. Gastroenterol., 2014, 20, 17804-17818.
14. Shieh, A.C. Biomechanical Forces Shape the Tumor Microenvironment. Ann. Biomed. Eng., 2011, 39, 1379-1389.
15. Shahneh, F.Z.; Baradaran, B.; Zamani, F.; Aghebati- Maleki, L. Tumor Angiogenesis and Anti-Angiogenic Therapies. Hum. Antibodies, 2013, 22, 15-19.
16. Cools-Lartigue, J.; Spicer, J.; Najmeh, S.; Ferri, L. Neutrophil Extracellular Traps in Cancer Progression. Cell. Mol. Life Sci. CMLS, 2014, 71, 4179-4194.
17. Mellinghoff, I.K.; Sawyers, C.L. The Emergence of Resistance to Targeted Cancer Therapeutics. Pharmacogenomics, 2002, 3, 603-623.
18. Khamisipour, G.; Jadidi-Niaragh, F.; Jahromi, A.S.; Zandi, K.; Hojjat-Farsangi, M. Mechanisms of Tumor Cell Resistance to the Current Targeted-Therapy Agents. Tumour Biol. J. Int. Soc. Oncodevelopmental Biol. Med., 2016, 37, 10021-10039.
19. Kenny, B.; Ballard, S.; Blagg, J.; Fox, D. Pharmacological Options in the Treatment of Benign Prostatic Hyperplasia. J. Med. Chem., 1997, 40, 1293-1315.
20. Zimmermann, G.R.; Lehár, J.; Keith, C.T. Multi-Target Therapeutics: When the Whole Is Greater than the Sum of the Parts. Drug Discov. Today, 2007, 12, 34-42.
21. Boran, A.D.W.; Iyengar, R. Systems Approaches to Polypharmacology and Drug Discovery. Curr. Opin. Drug Discov. Devel., 2010, 13, 297-309.
22. Peters, J.-U. Polypharmacology - Foe or Friend? J. Med. Chem., 2013, 56, 8955-8971.
23. Anighoro, A.; Bajorath, J.; Rastelli, G. Polypharmacology: Challenges and Opportunities in Drug Discovery. J. Med. Chem., 2014, 57, 7874-7887.
24. Azmi, A.S. Network Pharmacology for Cancer Drug Discovery: Are We There Yet? Future Med. Chem., 2012, 4, 939-941.
25. Faivre, S.; Demetri, G.; Sargent, W.; Raymond, E. Molecular Basis for Sunitinib Efficacy and Future Clinical Development. Nat. Rev. Drug Discov., 2007, 6, 734-745.
26. Yamauchi, T.; Yamauchi, N.; Ueki, K.; Sugiyama, T.; Waki, H.; Miki, H.; Tobe, K.; Matsuda, S.; Tsushima, T.; Yamamoto, T.; Fujita, T.; Taketani, Y.; Fukayama, M.; Kimura, S.; Yazaki, Y.; Nagai, R.; Kadowaki, T. Constitutive Tyrosine Phosphorylation of ErbB-2 via Jak2 by Autocrine Secretion of Prolactin in Human Breast Cancer. J. Biol. Chem., 2000, 275, 33937-33944.
27. Tsai, C.-J.; Nussinov, R. The Molecular Basis of Targeting Protein Kinases in Cancer Therapeutics. Semin. Cancer Biol., 2013, 23, 235-242.
28. Petrelli, A.; Giordano, S. From Single-To Multi-Target Drugs in Cancer Therapy: When Aspecificity Becomes an Advantage. Curr. Med. Chem., 2008, 15, 422-432.
29. Sweeny, L.; Zimmermann, T.M.; Liu, Z.; Rosenthal, E.L. Evaluation of Tyrosine Receptor Kinases in the Interactions of Head and Neck Squamous Cell Carcinoma Cells and Fibroblasts. Oral Oncol., 2012, 48, 1242-1249.
30. Dvorak, H.F. Tumor Stroma, Tumor Blood Vessels, and Antiangiogenesis Therapy. Cancer J. Sudbury Mass, 2015, 21, 237-243.
31. Paulsson, J.; Ehnman, M.; Östman, A. PDGF Receptors in Tumor Biology: Prognostic and Predictive Potential. Future Oncol. Lond. Engl., 2014, 10, 1695-1708.
32. Le Tourneau, C.; Faivre, S.; Raymond, E. New Developments in Multitargeted Therapy for Patients with Solid Tumours. Cancer Treat. Rev., 2008, 34, 37-48.
33. Roskoski, R. A Historical Overview of Protein Kinases and Their Targeted Small Molecule Inhibitors. Pharmacol. Res., 2015, 100, 1-23.
34. Jalencas, X.; Mestres, J. On the Origins of Drug Polypharmacology. MedChemComm, 2012, 4, 80-87.
35. Pardanani, A.; Tefferi, A. Imatinib Targets Other than Bcr/abl and Their Clinical Relevance in Myeloid Disorders. Blood, 2004, 104, 1931-1939.
36. Muller, A.J.; Young, J.C.; Pendergast, A.M.; Pondel, M.; Landau, N.R.; Littman, D.R.; Witte, O.N. BCR First Exon Sequences Specifically Activate the BCR/ABL Tyrosine Kinase Oncogene of Philadelphia Chromosome-Positive Human Leukemias. Mol. Cell. Biol., 1991, 11, 1785-1792.
37. Pendergast, A.M.; Muller, A.J.; Havlik, M.H.; Maru, Y.; Witte, O.N. BCR Sequences Essential for Transformation by the BCR-ABL Oncogene Bind to the ABL SH2 Regulatory Domain in a Non-Phosphotyrosine-Dependent Manner. Cell, 1991, 66, 161-171.
38. Jabbour, E.J.; Cortes, J.E.; Kantarjian, H.M. Resistance to Tyrosine Kinase Inhibition Therapy for Chronic Myelogenous Leukemia: A Clinical Perspective and Emerging Treatment Options. Clin. Lymphoma Myeloma Leuk., 2013, 13, 515-529.
39. Miller, G.D.; Bruno, B.J.; Lim, C.S. Resistant Mutations in CML and Ph(+)ALL - Role of Ponatinib. Biol. Targets Ther., 2014, 8, 243-254.
40. Lopes, L.F.; Bacchi, C.E. Imatinib Treatment for Gastrointestinal Stromal Tumour (GIST). J. Cell. Mol. Med., 2010, 14, 42-50.
41. Huss, S.; Elges, S.; Trautmann, M.; Sperveslage, J.; Hartmann, W.; Wardelmann, E. Classification of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: Implications for Therapy. Expert Rev. Anticancer Ther., 2015, 15, 623- 628.
42. Blanke, C.D.; Rankin, C.; Demetri, G.D.; Ryan, C.W.; von Mehren, M.; Benjamin, R.S.; Raymond, A.K.; Bramwell, V.H.C.; Baker, L.H.; Maki, R.G.; Tanaka, M.; Hecht, J.R.; Heinrich, M.C.; Fletcher, C.D.M.; Crowley, J.J.; Borden, E.C. Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033. J. Clin. Oncol., 2008, 26, 626-632.
43. Lee, J.-H.; Kim, Y.; Choi, J.-W.; Kim, Y.-S. Correlation of Imatinib Resistance with the Mutational Status of KIT and PDGFRA Genes in Gastrointestinal Stromal Tumors: A Meta-Analysis. J. Gastrointest. Liver Dis. JGLD, 2013, 22, 413-418.
44. Ostman, A.; Heldin, C.-H. PDGF Receptors as Targets in Tumor Treatment. Adv. Cancer Res., 2007, 97, 247-274.
45. Duffaud, F.; Le Cesne, A. Imatinib in the Treatment of Solid Tumours. Target. Oncol., 2009, 4, 45-56.
46. Handolias, D.; McArthur, G.A. Imatinib as Effective Therapy for Dermatofibrosarcoma Protuberans: Proof of Concept of the Autocrine Hypothesis for Cancer. Future Oncol. Lond. Engl., 2008, 4, 211-217.
47. Wilhelm, S.M.; Carter, C.; Tang, L.; Wilkie, D.; McNabola, A.; Rong, H.; Chen, C.; Zhang, X.; Vincent, P.; McHugh, M.; Cao, Y.; Shujath, J.; Gawlak, S.; Eveleigh, D.; Rowley, B.; Liu, L.; Adnane, L.; Lynch, M.; Auclair, D.; Taylor, I.; Gedrich, R.; Voznesensky, A.; Riedl, B.; Post, L.E.; Bollag, G.; Trail, P.A. BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis. Cancer Res., 2004, 64, 7099-7109.
48. Takahashi, S. Vascular Endothelial Growth Factor (VEGF), VEGF Receptors and Their Inhibitors for Antiangiogenic Tumor Therapy. Biol. Pharm. Bull., 2011, 34, 1785-1788.
49. Guida, T.; Anaganti, S.; Provitera, L.; Gedrich, R.; Sullivan, E.; Wilhelm, S.M.; Santoro, M.; Carlomagno, F. Sorafenib Inhibits Imatinib-Resistant KIT and Platelet-Derived Growth Factor Receptor Beta Gatekeeper Mutants. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res., 2007, 13, 3363-3369.
50. Zhang, W.; Konopleva, M.; Shi, Y.; McQueen, T.; Harris, D.; Ling, X.; Estrov, Z.; Quintás-Cardama, A.; Small, D.; Cortes, J.; Andreeff, M. Mutant FLT3: A Direct Target of Sorafenib in Acute Myelogenous Leukemia. J. Natl. Cancer Inst., 2008, 100, 184-198.
51. Yamamoto, Y.; Kiyoi, H.; Nakano, Y.; Suzuki, R.; Kodera, Y.; Miyawaki, S.; Asou, N.; Kuriyama, K.; Yagasaki, F.; Shimazaki, C.; Akiyama, H.; Saito, K.; Nishimura, M.; Motoji, T.; Shinagawa, K.; Takeshita, A.; Saito, H.; Ueda, R.; Ohno, R.; Naoe, T. Activating Mutation of D835 within the Activation Loop of FLT3 in Human Hematologic Malignancies. Blood, 2001, 97, 2434-2439.
52. Henderson, Y.C.; Ahn, S.-H.; Kang, Y.; Clayman, G.L. Sorafenib Potently Inhibits Papillary Thyroid Carcinomas Harboring RET/PTC1 Rearrangement. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res., 2008, 14, 4908-4914.
53. Giaccone, G. The Potential of Antiangiogenic Therapy in Non-Small Cell Lung Cancer. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res., 2007, 13, 1961-1970.
54. Dahut, W.L.; Scripture, C.; Posadas, E.; Jain, L.; Gulley, J.L.; Arlen, P.M.; Wright, J.J.; Yu, Y.; Cao, L.; Steinberg, S.M.; Aragon-Ching, J.B.; Venitz, J.; Jones, E.; Chen, C.C.; Figg, W.D. A Phase II Clinical Trial of Sorafenib in Androgen- Independent Prostate Cancer. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res., 2008, 14, 209-214.
55. Escudier, B.; Eisen, T.; Stadler, W.M.; Szczylik, C.; Oudard, S.; Siebels, M.; Negrier, S.; Chevreau, C.; Solska, E.; Desai, A.A.; Rolland, F.; Demkow, T.; Hutson, T.E.; Gore, M.; Freeman, S.; Schwartz, B.; Shan, M.; Simantov, R.; Bukowski, R.M.; TARGET Study Group. Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma. N. Engl. J. Med., 2007, 356, 125-134.
56. Ratain, M.J.; Eisen, T.; Stadler, W.M.; Flaherty, K.T.; Kaye, S.B.; Rosner, G.L.; Gore, M.; Desai, A.A.; Patnaik, A.; Xiong, H.Q.; Rowinsky, E.; Abbruzzese, J.L.; Xia, C.; Simantov, R.; Schwartz, B.; O'Dwyer, P.J. Phase II Placebo- Controlled Randomized Discontinuation Trial of Sorafenib in Patients with Metastatic Renal Cell Carcinoma. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol., 2006, 24, 2505-2512.
57. Flaherty, K.T. Sorafenib in Renal Cell Carcinoma. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res., 2007, 13, 747s - 752s.
58. Furuse, J. Growth Factors as Therapeutic Targets in HCC. Crit. Rev. Oncol. Hematol., 2008, 67, 8-15.
59. Brose, M.S.; Nutting, C.M.; Jarzab, B.; Elisei, R.; Siena, S.; Bastholt, L.; de la Fouchardiere, C.; Pacini, F.; Paschke, R.; Shong, Y.K.; Sherman, S.I.; Smit, J.W.A.; Chung, J.; Kappeler, C.; Peña, C.; Molnár, I.; Schlumberger, M.J.; DECISION investigators. Sorafenib in Radioactive Iodine- Refractory, Locally Advanced or Metastatic Differentiated Thyroid Cancer: A Randomised, Double-Blind, Phase 3 Trial. Lancet Lond. Engl., 2014, 384, 319-328.
60. Bergers, G.; Song, S.; Meyer-Morse, N.; Bergsland, E.; Hanahan, D. Benefits of Targeting Both Pericytes and Endothelial Cells in the Tumor Vasculature with Kinase Inhibitors. J. Clin. Invest., 2003, 111, 1287-1295.
61. Potapova, O.; Laird, A.D.; Nannini, M.A.; Barone, A.; Li, G.; Moss, K.G.; Cherrington, J.M.; Mendel, D.B. Contribution of Individual Targets to the Antitumor Efficacy of the Multitargeted Receptor Tyrosine Kinase Inhibitor SU11248. Mol. Cancer Ther., 2006, 5, 1280-1289.
62. Maki, R.G.; Fletcher, J.A.; Heinrich, M.C.; Morgan, J.A.; George, S.; Desai, J.; Scheu, K.; Fletcher, C.D.M.; Baum, C.; Demetri, G.D. Results from a Continuation Trial of SU11248 in Patients (pts) with Imatinib (IM)-Resistant Gastrointestinal Stromal Tumor (GIST). ASCO Meet. Abstr., 2005, 23, 9011.
63. Demetri, G.D.; van Oosterom, A.T.; Garrett, C.R.; Blackstein, M.E.; Shah, M.H.; Verweij, J.; McArthur, G.; Judson, I.R.; Heinrich, M.C.; Morgan, J.A.; Desai, J.; Fletcher, C.D.; George, S.; Bello, C.L.; Huang, X.; Baum, C.M.; Casali, P.G. Efficacy and Safety of Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumour after Failure of Imatinib: A Randomised Controlled Trial. Lancet Lond. Engl., 2006, 368, 1329-1338.
64. Motzer, R.J.; Michaelson, M.D.; Redman, B.G.; Hudes, G.R.; Wilding, G.; Figlin, R.A.; Ginsberg, M.S.; Kim, S.T.; Baum, C.M.; DePrimo, S.E.; Li, J.Z.; Bello, C.L.; Theuer, C.P.; George, D.J.; Rini, B.I. Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients with Metastatic Renal Cell Carcinoma. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol., 2006, 24, 16-24.
65. Motzer, R.J.; Rini, B.I.; Bukowski, R.M.; Curti, B.D.; George, D.J.; Hudes, G.R.; Redman, B.G.; Margolin, K.A.; Merchan, J.R.; Wilding, G.; Ginsberg, M.S.; Bacik, J.; Kim, S.T.; Baum, C.M.; Michaelson, M.D. Sunitinib in Patients with Metastatic Renal Cell Carcinoma. JAMA, 2006, 295, 2516-2524.
66. Motzer, R.J.; Hutson, T.E.; Tomczak, P.; Michaelson, M.D.; Bukowski, R.M.; Rixe, O.; Oudard, S.; Negrier, S.; Szczylik, C.; Kim, S.T.; Chen, I.; Bycott, P.W.; Baum, C.M.; Figlin, R.A. Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma. N. Engl. J. Med., 2007, 356, 115-124.
67. Frampton, J.E. Vandetanib: In Medullary Thyroid Cancer. Drugs, 2012, 72, 1423-1436.
68. McCarty, M.F.; Wey, J.; Stoeltzing, O.; Liu, W.; Fan, F.; Bucana, C.; Mansfield, P.F.; Ryan, A.J.; Ellis, L.M. ZD6474, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor with Additional Activity against Epidermal Growth Factor Receptor Tyrosine Kinase, Inhibits Orthotopic Growth and Angiogenesis of Gastric Cancer. Mol. Cancer Ther., 2004, 3, 1041-1048.
69. Ciardiello, F.; Bianco, R.; Caputo, R.; Caputo, R.; Damiano, V.; Troiani, T.; Melisi, D.; De Vita, F.; De Placido, S.; Bianco, A.R.; Tortora, G. Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Human Cancer Cells with Acquired Resistance to Antiepidermal Growth Factor Receptor Therapy. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res., 2004, 10, 784-793.
70. Wells, S.A.; Robinson, B.G.; Gagel, R.F.; Dralle, H.; Fagin, J.A.; Santoro, M.; Baudin, E.; Elisei, R.; Jarzab, B.; Vasselli, J.R.; Read, J.; Langmuir, P.; Ryan, A.J.; Schlumberger, M.J. Vandetanib in Patients with Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol., 2012, 30, 134-141.
71. Gandhi, L.; Jänne, P.A. Crizotinib for ALK-Rearranged Non-Small Cell Lung Cancer: A New Targeted Therapy for a New Target. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res., 2012, 18, 3737-3742.
72. Gridelli, C.; Peters, S.; Sgambato, A.; Casaluce, F.; Adjei, A.A.; Ciardiello, F. ALK Inhibitors in the Treatment of Advanced NSCLC. Cancer Treat. Rev., 2014, 40, 300-306.
73. Cui, J.J.; Tran-Dubé, M.; Shen, H.; Nambu, M.; Kung, P.- P.; Pairish, M.; Jia, L.; Meng, J.; Funk, L.; Botrous, I.; McTigue, M.; Grodsky, N.; Ryan, K.; Padrique, E.; Alton, G.; Timofeevski, S.; Yamazaki, S.; Li, Q.; Zou, H.; Christensen, J.; Mroczkowski, B.; Bender, S.; Kania, R.S.; Edwards, M.P. Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK). J. Med. Chem., 2011, 54, 6342-6363.
74. O'Bryant, C.L.; Wenger, S.D.; Kim, M.; Thompson, L.A. Crizotinib: A New Treatment Option for ALK-Positive Non-Small Cell Lung Cancer. Ann. Pharmacother., 2013, 47, 189-197.
75. Guo, L.; Zhang, H.; Shao, W.; Chen, B. Crizotinib as a Personalized Alternative for Targeted Anaplastic Lymphoma Kinase Rearrangement in Previously Treated Patients with Non-Small-Cell Lung Cancer. Drug Des. Devel. Ther., 2015, 9, 5491-5497.
76. Ou, S.-H.I. Crizotinib: A Novel and First-in-Class Multitargeted Tyrosine Kinase Inhibitor for the Treatment of Anaplastic Lymphoma Kinase Rearranged Non-Small Cell Lung Cancer and beyond. Drug Des. Devel. Ther., 2011, 5, 471-485.
77. Rothschild, S.I.; Gautschi, O. Crizotinib in the Treatment of Non-Small-Cell Lung Cancer. Clin. Lung Cancer, 2013, 14, 473-480.
78. Kwak, E.L.; Bang, Y.-J.; Camidge, D.R.; Shaw, A.T.; Solomon, B.; Maki, R.G.; Ou, S.-H.I.; Dezube, B.J.; Jänne, P.A.; Costa, D.B.; Varella-Garcia, M.; Kim, W.-H.; Lynch, T.J.; Fidias, P.; Stubbs, H.; Engelman, J.A.; Sequist, L.V.; Tan, W.; Gandhi, L.; Mino-Kenudson, M.; Wei, G.C.; Shreeve, S.M.; Ratain, M.J.; Settleman, J.; Christensen, J.G.; Haber, D.A.; Wilner, K.; Salgia, R.; Shapiro, G.I.; Clark, J.W.; Iafrate, A.J. Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer. N. Engl. J. Med., 2010, 363, 1693-1703.
79. Shaw, A.T.; Yeap, B.Y.; Solomon, B.J.; Riely, G.J.; Gainor, J.; Engelman, J.A.; Shapiro, G.I.; Costa, D.B.; Ou, S.-H.I.; Butaney, M.; Salgia, R.; Maki, R.G.; Varella-Garcia, M.; Doebele, R.C.; Bang, Y.-J.; Kulig, K.; Selaru, P.; Tang, Y.; Wilner, K.D.; Kwak, E.L.; Clark, J.W.; Iafrate, A.J.; Camidge, D.R. Effect of Crizotinib on Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Harbouring ALK Gene Rearrangement: A Retrospective Analysis. Lancet Oncol., 2011, 12, 1004-1012.
80. Camidge, D.R.; Bang, Y.-J.; Kwak, E.L.; Iafrate, A.J.; Varella- Garcia, M.; Fox, S.B.; Riely, G.J.; Solomon, B.; Ou, S.-H.I.; Kim, D.-W.; Salgia, R.; Fidias, P.; Engelman, J.A.; Gandhi, L.; Jänne, P.A.; Costa, D.B.; Shapiro, G.I.; Lorusso, P.; Ruffner, K.; Stephenson, P.; Tang, Y.; Wilner, K.; Clark, J.W.; Shaw, A.T. Activity and Safety of Crizotinib in Patients with ALK-Positive Non-Small-Cell Lung Cancer: Updated Results from a Phase 1 Study. Lancet Oncol., 2012, 13, 1011-1019.
81. Iacono, D.; Chiari, R.; Metro, G.; Bennati, C.; Bellezza, G.; Cenci, M.; Ricciuti, B.; Sidoni, A.; Baglivo, S.; Minotti, V.; Crinò, L. Future Options for ALK-Positive Non-Small Cell Lung Cancer. Lung Cancer, 2015, 87, 211-219.
82. Kanaan, Z.; Kloecker, G.H.; Paintal, A.; Perez, C.A. Novel Targeted Therapies for Resistant ALK-Rearranged Non- Small-Cell Lung Cancer: Ceritinib and beyond. OncoTargets Ther., 2015, 8, 885-892.
83. Toyokawa, G.; Seto, T. ALK Inhibitors: What Is the Best Way to Treat Patients with ALK+ Non-Small-Cell Lung Cancer? Clin. Lung Cancer, 2014, 15, 313-319.
84. Shaw, A.T.; Kim, D.-W.; Nakagawa, K.; Seto, T.; Crinó, L.; Ahn, M.-J.; De Pas, T.; Besse, B.; Solomon, B.J.; Blackhall, F.; Wu, Y.-L.; Thomas, M.; O'Byrne, K.J.; Moro-Sibilot, D.; Camidge, D.R.; Mok, T.; Hirsh, V.; Riely, G.J.; Iyer, S.; Tassell, V.; Polli, A.; Wilner, K.D.; Jänne, P.A. Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer. N. Engl. J. Med., 2013, 368, 2385-2394.
85. Weitzman, S.P.; Cabanillas, M.E. The Treatment Landscape in Thyroid Cancer: A Focus on Cabozantinib. Cancer Manag. Res., 2015, 7, 265-278.
86. Cancer Genome Atlas Research Network. Integrated Genomic Characterization of Papillary Thyroid Carcinoma. Cell, 2014, 159, 676-690.
87. Gherardi, E.; Birchmeier, W.; Birchmeier, C.; Vande Woude, G. Targeting MET in Cancer: Rationale and Progress. Nat. Rev. Cancer, 2012, 12, 89-103.
88. Aftab, D.T.; McDonald, D.M. MET and VEGF: Synergistic Targets in Castration-Resistant Prostate Cancer. Clin. Transl. Oncol. Off. Publ. Fed. Span. Oncol. Soc. Natl. Cancer Inst. Mex., 2011, 13, 703-709.
89. Shojaei, F.; Lee, J.H.; Simmons, B.H.; Wong, A.; Esparza, C.O.; Plumlee, P.A.; Feng, J.; Stewart, A.E.; Hu-Lowe, D.D.; Christensen, J.G. HGF/c-Met Acts as an Alternative Angiogenic Pathway in Sunitinib-Resistant Tumors. Cancer Res., 2010, 70, 10090-10100.
90. Kurzrock, R.; Sherman, S.I.; Ball, D.W.; Forastiere, A.A.; Cohen, R.B.; Mehra, R.; Pfister, D.G.; Cohen, E.E.W.; Janisch, L.; Nauling, F.; Hong, D.S.; Ng, C.S.; Ye, L.; Gagel, R.F.; Frye, J.; Müller, T.; Ratain, M.J.; Salgia, R. Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients with Medullary Thyroid Cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol., 2011, 29, 2660- 2666.
91. Nguyen, L.; Holland, J.; Miles, D.; Engel, C.; Benrimoh, N.; O'Reilly, T.; Lacy, S. Pharmacokinetic (PK) Drug Interaction Studies of Cabozantinib: Effect of CYP3A Inducer Rifampin and Inhibitor Ketoconazole on Cabozantinib Plasma PK and Effect of Cabozantinib on CYP2C8 Probe Substrate Rosiglitazone Plasma PK. J. Clin. Pharmacol., 2015, 55, 1012-1023.
92. Bartram, C.R.; de Klein, A.; Hagemeijer, A.; van Agthoven, T.; Geurts van Kessel, A.; Bootsma, D.; Grosveld, G.; Ferguson-Smith, M.A.; Davies, T.; Stone, M. Translocation of c-Ab1 Oncogene Correlates with the Presence of a Philadelphia Chromosome in Chronic Myelocytic Leukaemia. Nature, 1983, 306, 277-280.
93. Rowley, J.D. Letter: A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia Identified by Quinacrine Fluorescence and Giemsa Staining. Nature, 1973, 243, 290-293.
94. Ren, R. The Molecular Mechanism of Chronic Myelogenous Leukemia and Its Therapeutic Implications: Studies in a Murine Model. Oncogene, 2002, 21, 8629-8642.
95. Woessner, D.W.; Lim, C.S.; Deininger, M.W. Development of an Effective Therapy for Chronic Myelogenous Leukemia. Cancer J. Sudbury Mass, 2011, 17, 477-486.
96. Thomas, D.A. Philadelphia Chromosome Positive Acute Lymphocytic Leukemia: A New Era of Challenges. Hematol. Educ. Program Am. Soc. Hematol. Am. Soc. Hematol. Educ. Program, 2007, 435-443.
97. Shah, N.P.; Skaggs, B.J.; Branford, S.; Hughes, T.P.; Nicoll, J.M.; Paquette, R.L.; Sawyers, C.L. Sequential ABL Kinase Inhibitor Therapy Selects for Compound Drug- Resistant BCR-ABL Mutations with Altered Oncogenic Potency. J. Clin. Invest., 2007, 117, 2562-2569.
98. O'Hare, T.; Shakespeare, W.C.; Zhu, X.; Eide, C.A.; Rivera, V.M.; Wang, F.; Adrian, L.T.; Zhou, T.; Huang, W.-S.; Xu, Q.; Metcalf, C.A.; Tyner, J.W.; Loriaux, M.M.; Corbin, A.S.; Wardwell, S.; Ning, Y.; Keats, J.A.; Wang, Y.; Sundaramoorthi, R.; Thomas, M.; Zhou, D.; Snodgrass, J.; Commodore, L.; Sawyer, T.K.; Dalgarno, D.C.; Deininger, M.W.N.; Druker, B.J.; Clackson, T. AP24534, a Pan- BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation- Based Resistance. Cancer Cell, 2009, 16, 401-412.
99. O'Hare, T.; Walters, D.K.; Stoffregen, E.P.; Jia, T.; Manley, P.W.; Mestan, J.; Cowan-Jacob, S.W.; Lee, F.Y.; Heinrich, M.C.; Deininger, M.W.N.; Druker, B.J. In Vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants. Cancer Res., 2005, 65, 4500-4505.
100. Zhou, T.; Parillon, L.; Li, F.; Wang, Y.; Keats, J.; Lamore, S.; Xu, Q.; Shakespeare, W.; Dalgarno, D.; Zhu, X. Crystal Structure of the T315I Mutant of AbI Kinase. Chem. Biol. Drug Des., 2007, 70, 171-181.
101. Zhou, T.; Commodore, L.; Huang, W.-S.; Wang, Y.; Thomas, M.; Keats, J.; Xu, Q.; Rivera, V.M.; Shakespeare, W.C.; Clackson, T.; Dalgarno, D.C.; Zhu, X. Structural Mechanism of the Pan-BCR-ABL Inhibitor Ponatinib (AP24534): Lessons for Overcoming Kinase Inhibitor Resistance. Chem. Biol. Drug Des., 2011, 77, 1-11.
102. Huang, W.-S.; Metcalf, C.A.; Sundaramoorthi, R.; Wang, Y.; Zou, D.; Thomas, R.M.; Zhu, X.; Cai, L.; Wen, D.; Liu, S.; Romero, J.; Qi, J.; Chen, I.; Banda, G.; Lentini, S.P.; Das, S.; Xu, Q.; Keats, J.; Wang, F.; Wardwell, S.; Ning, Y.; Snodgrass, J.T.; Broudy, M.I.; Russian, K.; Zhou, T.; Commodore, L.; Narasimhan, N.I.; Mohemmad, Q.K.; Iuliucci, J.; Rivera, V.M.; Dalgarno, D.C.; Sawyer, T.K.; Clackson, T.; Shakespeare, W.C. Discovery of 3- [2- (Imidazo [1, 2-B]pyridazin-3-Yl)ethynyl]-4-Methyl-N-{4- [(4-Methylpiperazin-1-Yl)methyl]-3- (trifluoromethyl)phenyl}benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant. J. Med. Chem., 2010, 53, 4701-4719.
103. Cortes, J.E.; Kantarjian, H.; Shah, N.P.; Bixby, D.; Mauro, M.J.; Flinn, I.; O'Hare, T.; Hu, S.; Narasimhan, N.I.; Rivera, V.M.; Clackson, T.; Turner, C.D.; Haluska, F.G.; Druker, B.J.; Deininger, M.W.N.; Talpaz, M. Ponatinib in Refractory Philadelphia Chromosome-Positive Leukemias. N. Engl. J. Med., 2012, 367, 2075-2088.
104. Cortes, J.E.; Kim, D.-W.; Pinilla-Ibarz, J.; le Coutre, P.; Paquette, R.; Chuah, C.; Nicolini, F.E.; Apperley, J.F.; Khoury, H.J.; Talpaz, M.; DiPersio, J.; DeAngelo, D.J.; Abruzzese, E.; Rea, D.; Baccarani, M.; Müller, M.C.; Gambacorti- Passerini, C.; Wong, S.; Lustgarten, S.; Rivera, V.M.; Clackson, T.; Turner, C.D.; Haluska, F.G.; Guilhot, F.; Deininger, M.W.; Hochhaus, A.; Hughes, T.; Goldman, J.M.; Shah, N.P.; Kantarjian, H.; PACE Investigators. A Phase 2 Trial of Ponatinib in Philadelphia Chromosome- Positive Leukemias. N. Engl. J. Med., 2013, 369, 1783- 1796.
105. Wilhelm, S.M.; Dumas, J.; Adnane, L.; Lynch, M.; Carter, C.A.; Schütz, G.; Thierauch, K.-H.; Zopf, D. Regorafenib (BAY 73-4506): A New Oral Multikinase Inhibitor of Angiogenic, Stromal and Oncogenic Receptor Tyrosine Kinases with Potent Preclinical Antitumor Activity. Int. J. Cancer, 2011, 129, 245-255.
106. Abou-Elkacem, L.; Arns, S.; Brix, G.; Gremse, F.; Zopf, D.; Kiessling, F.; Lederle, W. Regorafenib Inhibits Growth, Angiogenesis, and Metastasis in a Highly Aggressive, Orthotopic Colon Cancer Model. Mol. Cancer Ther., 2013, 12, 1322-1331.
107. Mross, K.; Frost, A.; Steinbild, S.; Hedbom, S.; Büchert, M.; Fasol, U.; Unger, C.; Krätzschmar, J.; Heinig, R.; Boix, O.; Christensen, O. A Phase I Dose-Escalation Study of Regorafenib (BAY 73-4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res., 2012, 18, 2658-2667.
108. Strumberg, D.; Scheulen, M.E.; Schultheis, B.; Richly, H.; Frost, A.; Büchert, M.; Christensen, O.; Jeffers, M.; Heinig, R.; Boix, O.; Mross, K. Regorafenib (BAY 73-4506) in Advanced Colorectal Cancer: A Phase I Study. Br. J. Cancer, 2012, 106, 1722-1727.
109. Grothey, A.; Van Cutsem, E.; Sobrero, A.; Siena, S.; Falcone, A.; Ychou, M.; Humblet, Y.; Bouché, O.; Mineur, L.; Barone, C.; Adenis, A.; Tabernero, J.; Yoshino, T.; Lenz, H.-J.; Goldberg, R.M.; Sargent, D.J.; Cihon, F.; Cupit, L.; Wagner, A.; Laurent, D.; CORRECT Study Group. Regorafenib Monotherapy for Previously Treated Metastatic Colorectal Cancer (CORRECT): An International, Multicentre, Randomised, Placebo-Controlled, Phase 3 Trial. Lancet Lond. Engl., 2013, 381, 303-312.
110. Li, J.; Qin, S.; Xu, R.; Yau, T.C.C.; Ma, B.; Pan, H.; Xu, J.; Bai, Y.; Chi, Y.; Wang, L.; Yeh, K.-H.; Bi, F.; Cheng, Y.; Le, A.T.; Lin, J.-K.; Liu, T.; Ma, D.; Kappeler, C.; Kalmus, J.; Kim, T.W.; CONCUR Investigators. Regorafenib plus Best Supportive Care versus Placebo plus Best Supportive Care in Asian Patients with Previously Treated Metastatic Colorectal Cancer (CONCUR): A Randomised, Double- Blind, Placebo-Controlled, Phase 3 Trial. Lancet Oncol., 2015, 16, 619-629.
111. Ganesan, A. Multitarget Drugs: An Epigenetic Epiphany. ChemMedChem, 2016, 11, 1227-1241.
112. Naselli, F.; Belshaw, N.J.; Gentile, C.; Tutone, M.; Tesoriere, L.; Livrea, M.A.; Caradonna, F. Phytochemical Indicaxanthin Inhibits Colon Cancer Cell Growth and Affects the DNA Methylation Status by Influencing Epigenetically Modifying Enzyme Expression and Activity. J. Nutr. Nutr., 2015, 8, 114-127.
113. Galloway, T.J.; Wirth, L.J.; Colevas, A.D.; Gilbert, J.; Bauman, J.E.; Saba, N.F.; Raben, D.; Mehra, R.; Ma, A.W.; Atoyan, R.; Wang, J.; Burtness, B.; Jimeno, A. A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res., 2015, 21, 1566-1573.
114. Mahboobi, S.; Sellmer, A.; Winkler, M.; Eichhorn, E.; Pongratz, H.; Ciossek, T.; Baer, T.; Maier, T.; Beckers, T. Novel Chimeric Histone Deacetylase Inhibitors: A Series of Lapatinib Hybrides as Potent Inhibitors of Epidermal Growth Factor Receptor (EGFR), Human Epidermal Growth Factor Receptor 2 (HER2), and Histone Deacetylase Activity. J. Med. Chem., 2010, 53, 8546-8555.
115. Qian, C.; Lai, C.-J.; Bao, R.; Wang, D.-G.; Wang, J.; Xu, G.-X.; Atoyan, R.; Qu, H.; Yin, L.; Samson, M.; Zifcak, B.; Ma, A.W.S.; DellaRocca, S.; Borek, M.; Zhai, H.-X.; Cai, X.; Voi, M. Cancer Network Disruption by a Single Molecule Inhibitor Targeting Both Histone Deacetylase Activity and Phosphatidylinositol 3-Kinase Signaling. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res., 2012, 18, 4104-4113.
116. Chen, L.; Wilson, D.; Jayaram, H.N.; Pankiewicz, K.W. Dual Inhibitors of Inosine Monophosphate Dehydrogenase and Histone Deacetylases for Cancer Treatment. J. Med. Chem., 2007, 50, 6685-6691.
117. Niedzwiecki, A.; Roomi, M.W.; Kalinovsky, T.; Rath, M. Anticancer Efficacy of Polyphenols and Their Combinations. Nutrients, 2016, 8.
118. Naselli, F.; Tesoriere, L.; Caradonna, F.; Bellavia, D.; Attanzio, A.; Gentile, C.; Livrea, M.A. Anti-Proliferative and pro-Apoptotic Activity of Whole Extract and Isolated Indicaxanthin from Opuntia Ficus-Indica Associated with Re-Activation of the Onco-Suppressor p16(INK4a) Gene in Human Colorectal Carcinoma (Caco-2) Cells. Biochem. Biophys. Res. Commun., 2014, 450, 652-658.
119. Catanzaro, I.; Caradonna, F.; Barbata, G.; Saverini, M.; Mauro, M.; Sciandrello, G. Genomic Instability Induced by α-Pinene in Chinese Hamster Cell Line. Mutagenesis, 2012, 27, 463-469.
120. Gentile, C.; Perrone, A.; Attanzio, A.; Tesoriere, L.; Livrea, M.A. Sicilian Pistachio (Pistacia Vera L.) Nut Inhibits Expression and Release of Inflammatory Mediators and Reverts the Increase of Paracellular Permeability in IL-1β- Exposed Human Intestinal Epithelial Cells. Eur. J. Nutr., 2015, 54, 811-821.
121. Nandakumar, V.; Singh, T.; Katiyar, S.K. Multi-Targeted Prevention and Therapy of Cancer by Proanthocyanidins. Cancer Lett., 2008, 269, 378-387.
122. Welch, D.R.; Tomasovic, S.P. Implications of Tumor Progression on Clinical Oncology. Clin. Exp. Metastasis, 1985, 3, 151-188.
123. Adams, J.M.; Strasser, A. Is Tumor Growth Sustained by Rare Cancer Stem Cells or Dominant Clones? Cancer Res., 2008, 68, 4018-4021.
124. Shackleton, M.; Quintana, E.; Fearon, E.R.; Morrison, S.J. Heterogeneity in Cancer: Cancer Stem Cells versus Clonal Evolution. Cell, 2009, 138, 822-829.